We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Janssen-Cilag Ltd

50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG, UK
Telephone: +44 1494 567 567
Fax: +44 1494 567 568
Medical Information Direct Line: +353 1 800 709 122
Medical Information e-mail: medinfo@janssen-cilag.co.uk
Customer Care direct line: +353 1 620 2300
Medical Information Facsimile: +44 (0) 1494 567 445
Patient Information Leaflet last updated on medicines.ie: 11/10/2017
PIL Stelara 45 mg Solution for Injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 11/10/2017 and displayed until Current
Reasons for adding or updating:
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Updated on 15/11/2016 and displayed until 11/10/2017
Reasons for adding or updating:
  • Change to section 1 - what the product is used for
  • Change to section 2 - use in children and adolescents
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Updated on 08/12/2015 and displayed until 15/11/2016
Reasons for adding or updating:
  • Product/presentation re-marketed
Updated on 03/09/2010 and displayed until 08/12/2015
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
  • PIL product / presentation discontinued
Updated on 17/03/2010 and displayed until 03/09/2010
Reasons for adding or updating:
  • Change to date of revision
  • Correction of spelling/typing errors
Updated on 23/07/2009 and displayed until 17/03/2010
Reasons for adding or updating:
  • New PIL for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Ustekinumab